ENNOGEN HEALTHCARE INTERNATIONAL LIMITED
Get an alert when ENNOGEN HEALTHCARE INTERNATIONAL LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£17M
+71.4% highest in 4 filed years
Net assets
£60M
-3.1% vs 2024
Employees
57
+5.6% highest in 4 filed years
Profit before tax
£1.6M
-81.3% first positive since 2023
Net assets
5-year trend · vs Health Care median
Accounts
5-year trend · Δ = latest vs prior filed period · latest reflected 2025-12-31
| Metric | Trend | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Δ vs prior |
|---|---|---|---|---|---|---|---|
| Turnover | — | £6,603,314 | £33,324,661 | £51,914,110 | £61,625,282 | +18.7% | |
| Operating profit | — | -£1,414,544 | -£1,194,518 | £9,563,256 | £4,294,501 | -55.1% | |
| Profit before tax | — | -£1,408,015 | -£2,129,138 | £8,787,215 | £1,639,136 | -81.3% | |
| Net profit | £0 | -£1,484,972 | -£3,295,140 | £4,753,985 | -£646,079 | -113.6% | |
| Cash | — | £5,040,859 | £3,153,260 | £9,876,703 | £16,929,216 | +71.4% | |
| Total assets less current liabilities | £1,000 | £60,916,028 | £57,559,344 | £62,362,522 | £82,979,025 | +33.1% | |
| Net assets | £1,000 | £60,916,028 | £57,525,888 | £62,302,076 | £60,391,900 | -3.1% | |
| Equity | £1,000 | £60,916,028 | £57,525,888 | £62,302,076 | £60,391,900 | -3.1% | |
| Average employees | — | 39 | 47 | 54 | 57 | +5.6% | |
| Wages | — | £686,816 | £2,476,020 | £3,473,668 | £3,634,447 | +4.6% | |
| Directors' remuneration | — | £24,367 | — | £112,571 | £142,130 | +26.3% |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|---|---|
| Operating margin | — | -21.4% | -3.6% | 18.4% | 7.0% | |
| Net margin | — | -22.5% | -9.9% | 9.2% | -1.0% | |
| Return on capital employed | — | -2.3% | -2.1% | 15.3% | 5.2% | |
| Current ratio | — | — | 0.98x | 1.03x | 1.19x | |
| Interest cover | — | — | -1.28x | 10.19x | 1.47x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- Forvis Mazars LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“Based on this assessment, the Directors have a reasonable expectation that the Company has adequate resources to continue in operational existence for at least twelve months from the date of approval of these financial statements. Accordingly, the Directors consider it appropriate to adopt the going concern basis in preparing the financial statements.”
Group structure
- ENNOGEN HEALTHCARE INTERNATIONAL LIMITED · parent
- Vitame Ltd 100%
- BTC Pharma s.r.o. 100%
Significant events
- “On 18 June 2025 the Group acquired from Teva UK, the ownership and marketing authorities to Capsaicin 0.075% (Axsain) and 0.025% (Zacin) cream for £31.5m including an upfront payment of £21.5m and contingent consideration of £3m which is expected to be paid on the delivery of certain milestones over the next 18 months.”
- “On 17 July 2025 the Group agreed a £150m finance facility in a syndicated agreement with three banks including Santander UK plc, Barclays Bank plc, and HSBC UK plc. The financing agreement comprises of capacity to borrow up to £50m through a term loan facility and up to £100m from a revolving credit facility.”
- “On completion, the Group repaid existing borrowings of £25.1m to Santander UK plc and drew down £27m of borrowings from the new term loan.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
5 active · 0 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| RUPRAI, Gurdev Singh | Director | 2020-12-23 | Jul 1960 | British |
| RUPRAI, Leanna | Director | 2025-10-01 | Apr 1993 | British |
| RUPRAI, Nikisha | Director | 2025-06-16 | Oct 1991 | British |
| RUPRAI, Roshan | Director | 2025-06-16 | Apr 1998 | British |
| TATE, Jason Rodney | Director | 2022-06-14 | May 1976 | English |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Ennogen Investments Ltd | Corporate entity | Shares 75–100% | 2022-01-01 | Active |
| Mr Gurdev Singh Ruprai | Individual | Shares 75–100% | 2020-12-23 | Ceased 2022-01-01 |
Filing timeline
Last 20 of 30 total filings
Material constitutional events — rename, articles re-file, resolution
- 2024-04-22 RESOLUTIONS Resolution
- 2024-04-22 MA Memorandum articles
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-06-25 | AA | accounts | Accounts with accounts type full | |
| 2026-01-14 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-10-28 | CH01 | officers | Change person director company with change date | |
| 2025-10-14 | AP01 | officers | Appoint person director company with name date | |
| 2025-09-25 | AA | accounts | Accounts with accounts type full | |
| 2025-07-24 | MR01 | mortgage | Mortgage create with deed with charge number charge creation date | |
| 2025-07-22 | MR04 | mortgage | Mortgage satisfy charge full | |
| 2025-06-19 | AP01 | officers | Appoint person director company with name date | |
| 2025-06-19 | AP01 | officers | Appoint person director company with name date | |
| 2025-01-08 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-11-11 | AA | accounts | Accounts with accounts type full | |
| 2024-04-22 | RESOLUTIONS | resolution | Resolution | |
| 2024-04-22 | MA | incorporation | Memorandum articles | |
| 2024-04-19 | MR01 | mortgage | Mortgage create with deed with charge number charge creation date | |
| 2024-04-15 | MR04 | mortgage | Mortgage satisfy charge full | |
| 2024-04-15 | MR04 | mortgage | Mortgage satisfy charge full | |
| 2024-03-20 | PSC02 | persons-with-significant-control | Notification of a person with significant control | |
| 2024-03-20 | PSC07 | persons-with-significant-control | Cessation of a person with significant control | |
| 2024-01-17 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2023-12-05 | AA | accounts | Accounts with accounts type full |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 7
- Capital events
- 0
- Officers appointed
- 1
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.